Using BM CD34+ cells obtained from AML patients, our present paper shows that the reintroduction of miR-22 could relieve the differentiation blockage and inhibit the growth of AML BM blasts, which also suggests its potential in AML therapy. Here, CD34 is linked to acute myeloid leukemia.